Moderna’s mRNA RSV vaccine delivers impressive Phase 3 trial results

Biotechnology company Moderna has announced promising results from a large Phase 3 trial testing an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The data show the vaccine is nearly 84% effective in preventing moderate disease, and the…








